title: Long term outcomes reporting the safety of breast conserving therapy compared to mastectomy: 20-year results of EORTC 10801.
abstract: Large multicenter clinical trials have demonstrated the safety of breast conserving surgery and radiation (BCT) compared to modified radical mastectomy (MRM). At 20 years follow-up, the European Organization of Research and Treatment of Cancer (EORTC) 10801 trial reports the outcomes of distant metastasis (DM) and overall survival (OS) for stage 1 and 2 breast cancers treated from 1980-1986. Even though BCT had a higher 10 years local-regional recurrence (LRR) at 20% compared to MRM (12%), no significant difference was identified in long term OS (44% in the BCT group and 39% in the MRM group) or time to DM. Factors associated with increased LRR were dependent on biologic characteristics including larger tumor size, lymph node metastasis, and receptor subtype. BCT should be offered in appropriate patients when complete resection can be achieved. Continued research evaluating the heterogeneity of breast cancer subtypes will help further guide local-regional therapy for continued improvement in LRR, DM, and OS.
authors.affiliation: Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, 1400 Pressler Blvd. Houston, TX 77030, USA.
authors.forename: Dalliah M
authors.initials: DM
authors.lastname: Black
authors.affiliation: Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, 1400 Pressler Blvd. Houston, TX 77030, USA.
authors.forename: Kelly K
authors.initials: KK
authors.lastname: Hunt
authors.affiliation: Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, 1400 Pressler Blvd. Houston, TX 77030, USA.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Mittendorf
keywords: Breast conserving therapy (BCT); distant metastasis (DM); local-regional recurrence (LRR); modified radical mastectomy (MRM); outcomes; overall survival (OS); safety
references.citation: J Natl Cancer Inst. 2000 Jul 19;92(14):1143-50
references.pmid: 10904087
references.citation: Ann Surg. 2013 Feb;257(2):173-9
references.pmid: 23291658
references.citation: Lancet Oncol. 2012 Apr;13(4):412-9
references.pmid: 22373563
references.citation: N Engl J Med. 2002 Oct 17;347(16):1233-41
references.pmid: 12393820
references.citation: Breast Cancer Res Treat. 2012 Jul;134(2):683-92
references.pmid: 22547108
references.citation: Semin Radiat Oncol. 2011 Jan;21(1):3-9
references.pmid: 21134648
references.citation: J Natl Cancer Inst Monogr. 1992;(11):15-8
references.pmid: 1627421
references.citation: J Clin Oncol. 2008 May 10;26(14):2373-8
references.pmid: 18413639
references.citation: Eur J Cancer. 2010 Dec;46(18):3219-32
references.pmid: 20817513